
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Null Results in Brief |
1 IARC, Lyon, France; 2 Dipartimento di Scienze dell'Uomo e dell'Ambiente, Universita' di Pisa, Pisa, Italy; 3 Institute of Hygiene, Public Health, Health Services and Management, Bucharest, Romania; 4 Institute of Carcinogenesis, Cancer Research Center, Moscow, Russia; 5 Department of Occupational and Environmental Epidemiology, Institute of Occupational Medicine, Lodz, Poland; 6 National Institute of Environmental Health, Budapest, Hungary; 7 Cancer Center and Maria Sklodowska Institute of Oncology, Warsaw, Poland; 8 Department of Occupational Health, Specialized State Health Institute, Banska Bystrica, Slovakia; 9 Institute of Hygiene and Epidemiology, Charles University, First Faculty of Medicine, Prague, Czech Republic; 10 Department of Epidemiology and Genetics, Masaryk Cancer Institute, Brno, Czech Republic; and 11 Department of Preventive Medicine, Palacky University of Medicine, Olomouc, Czech Republic
Requests for reprints: Federico Canzian, IARC, 150 Cours Albert Thomas, F-69372 Lyon 08, France. Phone: 33-4-72738698; Fax: 33-4-72738388. E-mail: canzian{at}iarc.fr
| Introduction |
|---|
|
|
|---|
and reactive oxygen species. This is known to result in activation of the nuclear factor
B transcription factor signal pathway, leading to up-regulation of various inflammation-related genes, including IL6 and COX2. IL-6 is a major cytokine that is expressed in tumor-infiltrating cells. Lung cancer patients have been shown to have significantly higher serum levels of IL-6 compared with healthy controls (1).
Cyclooxygenase 2 (COX-2) is a key rate-limiting enzyme that converts arachidonic acid into proinflammatory prostaglandins. COX2 is overexpressed in lung cancer, where its overexpression was reported as a poor prognostic factor in nonsmall cell lung cancer patients. Furthermore, several studies point to a chemopreventive effect of nonsteroidal anti-inflammatory drugs, of which COX-2 is a major target, in lung cancer patients (2).
The IL1B gene contains a single nucleotide polymorphism (SNP) in the promoter region at position -31 (rs1143627). This T/C transversion is 31 bp upstream of the transcription start site and the presence of the C allele causes disruption of a TATA box. Several SNPs in the COX2 gene have been identified. In particular, the COX2.8473 T > C (exon 10, 3' untranslated region, rs5275) polymorphism may affect mRNA stability, thereby causing more inflammation. The promoter IL6 -174 G > C (rs1800795) SNP is associated with levels of IL-6 protein and the C-reactive protein (3).
We previously investigated the association between these polymorphisms and lung cancer in a case-control study based on a Norwegian population. We found an increased risk of nonsmall cell lung cancer for the carriers of T allele of the IL1B -31C > T polymorphism (4) and the C allele of the COX2.8473 C > T polymorphism (5), as well as increased risk of squamous cell carcinoma for carriers of the polymorphism of the IL6 promoter and risk of squamous cell carcinoma of the lung (5).
| Hypothesis |
|---|
|
|
|---|
| Materials and Methods |
|---|
|
|
|---|
Genotyping
The population used for the present study is smaller than the total of subjects recruited because it includes subjects for whom good-quality DNA was available. DNAs were extracted from whole blood samples or normal tissue by use of QIAamp Blood kit (Qiagen, Hilden, Germany).
DNAs from cases and controls were randomized and mixed on PCR plates to assure that an equal number of cases and controls could be simultaneously analyzed. Genotyping was carried out using the Taqman assay (Applied Biosystems, Foster City, CA). Primers and probes used for genotyping and all experimental conditions were identical to those previously reported (4, 5).
Statistical Analysis
The frequency distribution of demographic variables and putative risk factors of lung cancer, including country of residence, age, sex, education, and smoking was examined for cases and controls. Former smokers were defined as smokers who quit smoking at least 2 years before interview or diagnosis. Tobacco pack-years were calculated as the product of smoking duration (years) and smoking intensity (packs per day). Hardy-Weinberg equilibrium (HWE) was separately tested in cases and in controls. We used logistic regression for multivariate analyses to assess the main effects of genetic polymorphisms on lung cancer risk. The primary end points of the analysis were odds ratios and associated confidence intervals. All the analyses were conducted with STATA software (StataCorp, College Station, TX).
| Results |
|---|
|
|
|---|
|
When subjects were stratified on the basis of smoking status, gender, histology, and age, we did not find any statistical difference in the distribution of genotypes among cases and controls (Table 1 and data not shown).
| Statistical Power |
|---|
|
|
|---|
= 0.05, two-sided test, and a codominant model. | Study Limitations |
|---|
|
|
|---|
The present study failed to reproduce any of the associations observed in our previous studies (4, 5). The most likely explanation is that the previous observations were chance findings.
| Conclusion |
|---|
|
|
|---|
| Footnotes |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Note: D. Campa and R. Hung were recipients of Special Training Awards from IARC.
Received 7/13/04; revised 7/20/04; accepted 9/ 9/04.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M. Ter-Minassian, R. Zhai, K. Asomaning, L. Su, W. Zhou, G. Liu, R. S. Heist, T. J. Lynch, J. C. Wain, X. Lin, et al. Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer Carcinogenesis, November 1, 2008; 29(11): 2147 - 2152. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Engels, X. Wu, J. Gu, Q. Dong, J. Liu, and M. R. Spitz Systematic Evaluation of Genetic Variants in the Inflammation Pathway and Risk of Lung Cancer Cancer Res., July 1, 2007; 67(13): 6520 - 6527. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. C. Sakoda, Y.-T. Gao, B. E. Chen, J. Chen, P. S. Rosenberg, A. Rashid, J. Deng, M.-C. Shen, B.-S. Wang, T.-Q. Han, et al. Prostaglandin-endoperoxide synthase 2 (PTGS2) gene polymorphisms and risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China Carcinogenesis, June 1, 2006; 27(6): 1251 - 1256. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |